ROIV Earnings & Financial Statements
Roivant Sciences Ltd.
$33.95
-$0.80(-2.30%)
45
Overall
--
Value
30
Tech
60
Quality
Market Cap
$25.10B
Volume
2.72M
52W Range
$15.25 - $42.50
Target Price
$48.15
ROIV earnings and financial statements: Roivant Sciences Ltd.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ROIV Annual Financial Statements
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $8.26M | $29.05M | $32.71M | $61.28M | $55.29M |
| Cost of revenue | $1.28M | $911.0K | $15.56M | $13.13M | $8.97M |
| Operating income | -$515.07M | -$1.00B | $4.50B | -$1.18B | -$1.35B |
| EBITDA | -$252.95M | -$660.68M | $4.60B | -$1.17B | -$903.50M |
| Net income | -$299.77M | -$171.98M | $4.35B | -$1.01B | -$845.26M |
| EPS (diluted) | $-0.54 | $-0.24 | $5.23 | $-2.84 | $-1.26 |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | $5.71B | $5.44B | $7.22B | $2.39B | $2.59B |
| Total liabilities | $416.27M | $249.74M | $773.95M | $782.02M | $523.70M |
| Shareholders’ equity | $4.53B | $4.69B | $5.97B | $1.16B | $1.66B |
| Cash and equivalents | $1.42B | $2.72B | $6.49B | $1.68B | $2.06B |
| Long-term debt | $96.29M | $90.33M | $45.02M | $428.99M | $272.49M |
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Operating cash flow | -$750.35M | -$839.45M | -$765.27M | -$843.39M | -$677.73M |
| Capital expenditure | -$8.21M | -$4.60M | -$1.38M | -$12.69M | -$17.44M |
| Free cash flow | -$758.56M | -$844.05M | -$766.65M | -$856.08M | -$695.16M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ROIV | $33.95 | -2.3% | 2.72M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |